NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
